Argenx Shares Slip in Q1 as Investors React to Earnings
Biotech firm Argenx saw its share price fall in the first quarter, attributed to weaker‑than‑expected sales and guidance. Analysts cite concerns over competitive pressures in the autoimmune market and note that the company is taking steps to strengthen its pipeline.
Реклама: Article Inline